Abstract
Pancreatic cancer is amongst the top ten fatal cancers of the Western world, accounting for 57 000 deaths per year in Europe and 29 000 deaths per year in the United States.1 It is particularly difficult to treat because of its inaccessible location, late presentation, and frequently aggressive tumour biology. Five-year survival in the 10–15% of affected patients who undergo potentially curative surgery is limited to 17–24%,2,3 whilst overall 5-year survival in all patients is less than 0.5%.4 Although significant improvements in surgical outcome have been obtained with increasing specialisation and case-load,3,5 and further benefits may be anticipated with earlier investigation and referral of high risk groups, 6 the role of adjuvant and neo-adjuvant treatment accompanying surgery remains uncertain.7-10 Interestingly, chemotherapy is the principal modality in the treatment of advanced pancreatic cancer.11
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Parkin DM, Muir CS, Whelan SL, et al. Cancer incidence in five continents, vol VI. Lyon: International Agency for Research on Cancer, 1992 (IARC Scientific Publications number 120)
Nitecki SS, Sarr MG, Colby, et al. Long-term survival after resection for ductal adenocarcinoma of the pancreas: is it really improving? Ann Surg 1995; 221:59–66
Birkmeyer JD, Warshaw AL, Finlayson STG, et al. Relationship between hospital volume and late survival after pancreatoduodenectomy. Surgery 1999; 126:178–183
Bramhall SR, Allum WH, Jones AG, et al. Incidence, treatment and survival in 13,560 patients with pancreatic cancer: an epidemiological study in the West Midlands. Br J Surg 1995; 82:111–115
Neoptolemos JP, Russell RCG, Bramhall SR, et al. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. Br J Surg 1997; 84:1370–1376
Wong T, Howes N, Threadgold J, et al. Molecular diagnosis of pancreatic ductal adenocarcinoma in high-risk patients. Pancreatology 2001; 1:486–509
Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 185; 120:899–903
Douglass HO. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006–2010
Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater: results of a controlled, prospective, randomised multicenter study. Eur J Cancer 1993; 5:698–703
Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999; 230:776–784
Magee CJ, Ghaneh P, Neoptolemos JP. Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 2002; 16:435–55
Jones L, Mosca F, Russell C, et al. Standard Kausch-Whipple pancreatoduodenectomy. Dig Surg 1999; 16:297–304
Pedrazzoli S, Di Carlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a Multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228:508–517
Mosca F, Giulianotti PC, Balestracci T, et al. Long-term survival in pancreatic cancer: pyloruspreserving vs Whipple pancreatoduodenectomy. Surgery 1997; 122:553–566
Trede M, Schwall G, Saeger H-D. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447–458
Allema JH, Reinders ME, Vangulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer 1995; 75:2069–2076
Yeo C, Abrams R, Grochow L, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival: a prospective, single institution experience. Ann Surg 1997; 225:621–633
Snow J. On the mode of communication of cholera. 2nd edn. London: John Churchill, 1860 (facsimile of 1936 reprinted edition published in 1965 by Hafner, New York)
Streptomycin in Tuberculosis Trials Committee, Medical Research Council. Streptomycin treatment in pulmonary tuberculosis: a Medical Research Council investigation. BMJ 1948; ii:769–82
van der Wijden CL, Overbeke JA. Audit of reports of randomised clinical trials published in one journal over 45 years. BMJ 1995; 311:918
Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. Lancet 2001; 357:1191–4
Moher D, Jones A, Lepage L, et al. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001; 285:1992–1995
Peto R, Baigent C. Trials: the next 50 years. Large scale randomised evidence of moderate benefits. BMJ 1998; 317:1170–1
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 1988; ii:349–360
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1–12
Neoptolemos JP, Dunn JA, Stocken DD, et al. European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358:1576–85
Neoptolemos JP, Stocken DD, Dunn JA, et al. European Study Group for Pancreatic Cancer. Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001; 234:758–68
Link KH, Formentini A, Leder G, et al. Resection and radiochemotherapy of pancreatic cancer — the future? Langenbecks Arch Surg 1998; 383:134–144
Abbruzzese JL. Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality. Semin Oncol 2002; 29:2–8
Neoptolemos JP, Cunningham D, Friess H, et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol 2003; 14:675–92
Rights and permissions
Copyright information
© 2004 Springer-Verlag London
About this chapter
Cite this chapter
Sutton, R. et al. (2004). Progress by Collaboration: ESPAC Studies. In: Pancreatic Disease. Springer, London. https://doi.org/10.1007/978-1-85233-904-3_5
Download citation
DOI: https://doi.org/10.1007/978-1-85233-904-3_5
Publisher Name: Springer, London
Print ISBN: 978-1-4471-3491-6
Online ISBN: 978-1-85233-904-3
eBook Packages: Springer Book Archive